TRIAL DATA
STRATEGIC-1 Trial Defines Optimal Treatment Sequence for RAS/BRAF Wild-Type Metastatic Colorectal Cancer — Signal Transduction and Targeted Therapy
The Phase III STRATEGIC-1 trial (NCT01910610) compared different sequences of chemotherapy combined with either anti-EGFR antibodies (cetuximab/panitumumab) or anti-angiogenic drugs (bevacizumab) in patients with RAS and BRAF wild-type metastatic colorectal cancer. The study aimed to determine the best order to use these treatments to maximize patient survival. RAS/BRAF wild-type tumors lack certain mutations and can respond to anti-EGFR therapy.
What this means
If your tumor is RAS and BRAF wild-type, this trial provides evidence about which targeted therapy to use first and how to sequence treatments over time. Ask your oncologist about your tumor's mutation status and how these findings apply to your treatment plan.